1. Topiramate affords neuroprotection in diabetic neuropathy model via downregulating spinal GFAP/inflammatory burden and improving neurofilament production.
- Author
-
Attia, Mohammed A., Soliman, Nema, Eladl, Mohamed Ahmed, Bilasy, Shymaa E., El-Abaseri, Taghrid B., Ali, Howaida S., Abbas, Faten, Ibrahim, Dalia, Osman, Noura M. S., Hashish, Abdullah A., Alshahrani, Asma, Mohamed, Abir S., and Zaitone, Sawsan A.
- Subjects
DIABETIC neuropathies ,CYTOPLASMIC filaments ,TOPIRAMATE ,SCIATIC nerve ,PAIN threshold ,SPINAL cord ,CINNAMON - Abstract
The current study aimed to test the neuroprotective action of topiramate in mouse peripheral diabetic neuropathy (DN) and explored some mechanisms underlying this action. Mice were assigned as vehicle group, DN group, DN + topiramate 10-mg/kg and DN + topiramate 30-mg/kg. Mice were tested for allodynia and hyperalgesia and then spinal cord and sciatic nerves specimens were examined microscopically and neurofilament heavy chain (NEFH) immunostaining was performed. Results indicated that DN mice had lower the hotplate latency time (0.46-fold of latency to licking) and lower von-Frey test pain threshold (0.6-fold of filament size) while treatment with topiramate increased these values significantly. Sciatic nerves from DN control mice showed axonal degeneration while spinal cords showed elevated GFAP (5.6-fold) and inflammatory cytokines (∼3- to 4-fold) but lower plasticity as indicated by GAP-43 (0.25-fold). Topiramate produced neuroprotection and suppressed spinal cord GFAP/inflammation but enhanced GAP-43. This study reinforces topiramate as neuroprotection and explained some mechanisms included in alleviating neuropathy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF